



Company Announcement

Vaccibody AS^{*)} – Notice of Extraordinary General Meeting

Oslo, Norway, December 15, 2021 – Vaccibody AS^{*)}, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, hereby calls for an Extraordinary General Meeting (EGM) to be held at meeting room VIA – Building G – Floor 0 in Gaustadalléen 21, Oslo, Norway at 10:00 CET on December 22, 2021.

The notice of the EGM is attached. All documents regarding the EGM are also available at the Company's website: www.nykode.com/media/news-and-announcements.

The following items are on the agenda: (i) Election of new chair of the board and changes to the board (ii) Remuneration to the chair of the board and board member.

Due to the ongoing corona virus pandemic, the Board encourages shareholders not to attend the general meeting in person, but rather to make use of the ability to vote by proxy. The proxy form will be found at the above weblink.

For further information, please see the Company's website or contact CFO Harald Gurvin. Please see below for contact details.

^{*)} Vaccibody AS is changing its company name to Nykode Therapeutics AS. The change of name was approved at an EGM on November 30, 2021.

About Nykode Therapeutics^{*)}

Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment cancer and infectious diseases. Nykode Therapeutics' modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and elicit efficacious clinical responses.

Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively out licensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumours and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode Therapeutics has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.



The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and collaborates with Adaptive Biotechnologies for COVID-19 T cell vaccine development.

Nykode Therapeutics' shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC (ticker will soon be changed). Further information about Nykode Therapeutics may be found at <http://www.nykode.com>

Contact for Nykode Therapeutics AS:

CFO Harald Gurvin
Nykode Therapeutics AS
Cell: +47 975 20 363
hgurvin@nykode.com

Nykode Therapeutics AS

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.